Health & Biotech
Investors frown as dental group Totally Smiles misses prospectus cashflow goal
Actinogen to expand clinical development program of its novel Alzheimer’s drug
Rhythm Biosciences thinks there’s a better way to find these cancer-causing polyps
These China-focused infant formula stocks are averaging 170pc one-year returns
Infant formula play Jatenergy is making less but burning less
Medical cannabis patients will buy more pot than dopers by 2022
Immuron’s diarrhoea solution pushes revenue to record level
The ‘world’s biggest legal pot dealer’ talks about the future of cannabis
Cannabis investor EVE gains 12pc after finalising lease of pot site to Hydroponics Co
Bod Australia is giving patients their first taste of its cannabis wafer
What’s next for Prana in move from Alzheimer’s to Parkinson’s
These 18 health start-ups are valued at more than $US1 billion each
Medical cannabis biotech Botanix just did a deal with the University of Queensland
QBL’s acquisition target now has cannabis licences; shares jump 21pc
Blood-tester Universal Biosensors is adding to the piggy bank but revenue has dropped
Radiologists call for CTC bowel cancer scans, but a better option is close
Medical software maker 1ST Group rockets 31pc on strong sales guidance
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
